- Home
- FLYE vs BIAF Comparison
FLYE vs BIAF Comparison
Compare FLYE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- BIAF
- Stock Information
- Founded
- FLYE 2018
- BIAF 2014
- Country
- FLYE United States
- BIAF United States
- Employees
- FLYE N/A
- BIAF N/A
- Industry
- FLYE Aerospace
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FLYE Industrials
- BIAF Health Care
- Exchange
- FLYE Nasdaq
- BIAF Nasdaq
- Market Cap
- FLYE 10.2M
- BIAF 12.2M
- IPO Year
- FLYE 2024
- BIAF 2022
- Fundamental
- Price
- FLYE $5.61
- BIAF $0.36
- Analyst Decision
- FLYE
- BIAF Hold
- Analyst Count
- FLYE 0
- BIAF 1
- Target Price
- FLYE N/A
- BIAF N/A
- AVG Volume (30 Days)
- FLYE 818.5K
- BIAF 12.1M
- Earning Date
- FLYE 08-18-2025
- BIAF 08-13-2025
- Dividend Yield
- FLYE N/A
- BIAF N/A
- EPS Growth
- FLYE N/A
- BIAF N/A
- EPS
- FLYE N/A
- BIAF N/A
- Revenue
- FLYE $25,427,163.00
- BIAF $8,809,228.00
- Revenue This Year
- FLYE N/A
- BIAF N/A
- Revenue Next Year
- FLYE N/A
- BIAF $20.00
- P/E Ratio
- FLYE N/A
- BIAF N/A
- Revenue Growth
- FLYE N/A
- BIAF 78.40
- 52 Week Low
- FLYE $1.65
- BIAF $0.16
- 52 Week High
- FLYE $33.60
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- BIAF 59.13
- Support Level
- FLYE N/A
- BIAF $0.27
- Resistance Level
- FLYE N/A
- BIAF $0.36
- Average True Range (ATR)
- FLYE 0.00
- BIAF 0.05
- MACD
- FLYE 0.00
- BIAF 0.01
- Stochastic Oscillator
- FLYE 0.00
- BIAF 97.52
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.